REVIEW ARTICLE

Pearls and pitfalls in lung cancer staging

1,2LUCIAN BEER, 3ANKUSH JAJODIA and 1HELMUT PROSCH
1Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
2Department of Radiology and Cancer Research UK, Cambridge, England, UK
3Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India

ABSTRACT
Lung cancer is the third most common cancer in the UK and is the leading cause of death. Radiology plays a central role in the diagnostic work-up of patients with suspected and known lung cancer. Tumour assessment includes both local staging, as well as distant staging. Local staging objectives include the assessment of technical resectability with regard to the evaluation of tumour size and invasion of surrounding structures. Distant staging objectives aim to identify distant metastasis in lymphatic and extra lymphatic tissues. CT, positron emission tomography/CT, MRI, and ultrasound are routinely used imaging techniques for staging in patients with lung cancer. In this review, we will consider the pitfalls of these examinations that radiologists potentially face during the work-up of patients with lung cancer.

INTRODUCTION
Radiologists are fundamentally involved in the diagnosis and treatment decision-making in patients with lung cancer and see patients with lung cancer at various stages of their journey. The radiologist is frequently the first contact, often at time of their initial diagnosis, which can either be during lung cancer screening examinations or during diagnostic examinations. Patients are then discussed within the multidisciplinary team (MDT) and in many cases, the next step in the diagnostic process is tumour tissue sampling, in which radiologists are also involved. Once the diagnosis of lung cancer is established, patients are staged based on the anatomical tumour extent. Finally, imaging examinations are used for treatment response assessment and for evaluation of disease recurrence. Each step comprises peculiarities and challenges for radiologists. In this review, we will focus on the pearls and pitfalls of lung cancer staging from a radiology perspective.

The eighth edition addresses several limitations of the seventh edition, although several issues persist.

In the TNM staging system, the T descriptor describes the local tumour extent, the N descriptor the involvement of hilar or mediastinal lymph nodes, and the M descriptor intra- and extrathoracic distant metastases.

T-descriptors
The T descriptor indicates the size of the primary tumour and its extension into neighbouring structures, such as the chest wall or the mediastinum. Furthermore, the T descriptor is also used to describe ipsilateral pulmonary metastases.

Based on their size, tumours are categorized as T1 tumours with a maximum diameter of less than 3 cm, T2 tumours with a maximum diameter between 5 cm and 7 cm, and T3 tumours with a maximum diameter of more than 7 cm. T1 and T2 tumours are further subclassified in T1a, T1b, and T1c, and T2a and T2b in 1 cm increments to allow an even better prognostic classification.

How to measure tumour size
The TNM manifest defines the way in which radiologists should measure lung cancer for TNM staging. For solid tumours, the single largest dimension measured in one of the three standard planes (axial, coronal, sagittal) using thin sections (1 mm) should be measured and used for the T descriptor (Figure 1A).

In part-solid tumours, the
largest tumour dimension, including the ground-glass (GG) part, should be recorded, but the staging is based on the largest diameter of the solid component. The solid component in part-solid, non-mucinous, lung adenocarcinomas correlates with an invasive adenocarcinoma pattern, while the GG component correlates with a lepidic growth pattern.\(^3\)

Pure GG lesions with the largest diameter between 0.5 cm and 3 cm are classified as T1\(\text{is}\), indicating that such pure GG lesions are most likely in situ tumours (Figure 1C). Pure GG lesions smaller than 0.5 cm are not staged, as the probability of such lesions being malignant is very low. Pure GG lesions larger than 3 cm are classified as T1a.

Tumour size should be recorded in centimetres and include millimetre increments. It is recommended that thin slices (1 mm) be used, as thick-slice reconstructions (1.5 to 5 mm) could mask small solid components. These tumours would, therefore, mistakenly be classified as pure GG tumours (Figure 2).

In the rare cases of part-solid tumours with several solid components, the radiologist should measure the long axis of the largest solid component.\(^3\)

Atelectasis

In tumours in which the obstructive effect of the tumour leads to an atelectasis or a post-obstructive pneumonia, a reliable determination of tumour size is not possible. Consequently, partial or total atelectasis of a lobe or entire lung side or a post-obstructive pneumonia are defined as T2.

In patients with central tumours leading to an atelectasis, in which a delineation of tumours is necessary to limit the radiation field, PET/CT or PET/MRI are of help in identifying the obstructing tumour\(^5\) (Figure 3).

Infiltration of the chest wall or the diaphragm

While an infiltration of the chest wall is defined as T3, an infiltration of the diaphragm is classified as T4 disease.\(^7\) Multiplanar reconstructions (MPRs) using sagittal and coronal views should always be used to assess an infiltration of these structures, as axial reconstruction might understate diaphragmatic infiltration.\(^6\)

Unequivocal signs of an infiltration include the evidence of tumour masses that have infiltrated neighbouring structures. In case of the chest wall, the best evidence are rib erosions or a broad extension of tumour masses into the intercostal space.

Less reliable signs of an infiltration of neighbouring structures are impaired respiratory movement or a thickening of the pleura. Both of these signs, however, have only a limited positive predictive value, as inflammatory reactions around tumours may also result in the same signs.

MRI, especially using dynamic CINE sequences, has a higher accuracy (77%) compared to CT (47%) for the evaluation of chest wall and diaphragm infiltration.\(^7\) In particular, the sensitivity of up to 100% for MRI is superior compared to the 60% sensitivity...
of conventional CT. Tumours that infiltrate the diaphragm and/or chest wall do not follow the normal respiratory movement. This can be visualised on MRI and used for staging purposes. Similarly, dynamic CT examinations have higher sensitivity and specificity compared to conventional static CT.

Superior sulcus tumours (Pancoast tumours) are classified as at least T3 tumours because of their chest wall infiltration. In the presence of invasion of the brachial plexus above C8, the vertebral body, spinal canal, or subclavian vessels, these tumours are upstaged to T4.

Infiltration of the mediastinum
An infiltration of the mediastinum is defined as T4. The mediastinal structures that define T4 are the mediastinal fat, great vessels, the oesophagus, the trachea, and the heart. While an unequivocal invasion of the mediastinal fat is defined as T4, an invasion of the mediastinal parietal pleura alone is defined as T3. Therefore, tumour contact with the mediastinal pleura without direct or indirect signs of invasion is not automatically staged as T4. Tumour contact with a length of more than 3 cm or an obtuse angle between the tumour and the mediastinum are indirect signs of mediastinal infiltration. In contrast, direct infiltration of the mediastinal fat or of the structure contained within the mediastinum (e.g. heart, oesophagus) are staged as T4. The sensitivity and specificity for the assessment of mediastinal invasion by CT ranges from 40 to 78% and 69 to 99% (summarised in Seo et al., respectively), while it is up to 100 and 93% for cine MR images.

In the staging system, great vessels are defined as the aorta, the superior and inferior vena cava, the main pulmonary trunk, and the intrapericardial portions of the pulmonary arteries and veins. While the aorta, the superior and inferior vena cava, as well as the main pulmonary trunk can be identified easily on CT, the border between the intra- and extrapericardial portions of the pulmonary arteries and veins cannot, because the pericardial fold cannot be visualised with CT. The pericardial fold around the right pulmonary artery may be defined by an imaginary line at the mid-half of the superior vena cava, while the pericardial fold of the left pulmonary artery is roughly 1 cm from the bifurcation of the main pulmonary artery (Figure 4).

Intrapulmonary metastases
Intrapulmonary metastases are classified based on their location. Pulmonary metastases in the same lobe as the primary tumour are classified as T3, while metastases in another lobe on the same side as the primary as T4, and metastases to the contralateral lung as M1a.

While this classification of pulmonary metastases sounds straightforward, it may lead to overstaging if the suspected pulmonary metastases are not verified histologically, as most pulmonary nodules detected in patients with lung cancer are benign. Consequently, additional pulmonary nodules that might have an impact on treatment should be verified histologically to determine whether they are malignant.

If malignant, the radiologist has to discriminate intrapulmonary metastases from a second primary.

Table 1 summarises the radiological criteria by which to distinguish a second primary from a metastasis. Intrapulmonary metastases should be considered for solid lung cancers that have a separate tumour nodule(s) with a similar solid appearance and with (likely) matching histologic appearance (Figure 5).

Second primary lung cancers should be staged separately, each with a T, N, and M descriptor. For example, a patient with a 3.5 cm adenocarcinoma of the left upper lobe, a 2.4 cm squamous cell carcinoma of the right lower lobe, and with a metastatic lymph node in R11 without evidence of systemic metastasis, should be classified as having a T2aN0M0 adenocarcinoma and a T1cN1Mo squamous cell carcinoma.
It is important to note that the above-mentioned guidance for the staging of primary lung cancer should not be applied in patients with multiple subsolid tumour nodules (either pure GG nodules or part-solid nodules) or in patients with pneumonic-type lung cancer. For patients with multifocal GG or part-solid nodules, the T descriptor is based on the highest T lesion (#/m) indicating the number of tumour nodules. The T(#/m) classification should be applied independently whether the GG/part-solid lesions are in the same or in different ipsi- or contralateral lobes. In contrast, for pneumonic-type lung adenocarcinoma, the T is based on size for T3 if the tumour is limited to one single lobe, and T4 or M1a.

Figure 3. (a) A 65-year-old patient with NSCLC and right upper lobe atelectasis. On the contrast-enhanced CT (b) an inhomogeneous mass is seen at the level of the right hilum that obliterates the right upper lobe bronchus. The exact tumour diameter cannot be assessed accurately. (c) FDG -PET/CT shows focally increased FDG uptake in the tumour, while the post-stenotic atelectatic lung shows only a moderate FDG uptake. In this patient, the metabolic information helps to correctly assess tumour dimension. FDG, fludeoxyglucose; NSCLC, non-small cell lung cancer; PET, positron emission tomography.

Figure 4. (a) Axial contrast-enhanced CT of a 55-year-old female patient with an NSCLC at the left hilum. As the distance between the main pulmonary trunk and the tumour is more than 10 mm, it is classified as T3 disease. (b) In contrast, in this 73-year-old male patient with NSCLC, the tumour is in direct contact with the main pulmonary artery and left main pulmonary artery, and therefore, staged as T4. NSCLC, non-small cell lung cancer.

Table 1. Criteria by which to distinguish second primary tumours vs metastasis (adapted from Detterbeck et al10)

| Relative criteria that favour synchronous tumours | Relative criteria that favour metastasis |
|--------------------------------------------------|---------------------------------------|
| Different radiography appearance (i.e. shape, density) | Same radiographic appearance |
| Different metabolic activity | Significant nodal or systemic metastases |
| Different growth rates (if previous imaging is available) | Relative criteria that favour metastasis |
| Absence of nodal or systemic metastasis | Similar growth rates (if previous imaging is available) |
if in different ipsilateral or contralateral lobes, respectively. Both tumour types use a single N and M staging, regardless of how many GG/part-solid nodules are present.

Table 2 summarises potential pitfalls that can occur during the T-descriptor assessment and solutions to overcome these limitations.

### Nodal disease

The N-descriptor remained unchanged in the eighth TNM edition compared to the seventh edition. Lymph node metastases to the ipsilateral hilum are classified as N1, lymph node metastases to the ipsilateral mediastinum or the subcarinal lymph nodes as N2, and contralateral mediastinal or supraclavicular lymph node metastases as N3.

Although CT is routinely used for the initial staging of patients with lung cancer, it has limited accuracy for the detection of thoracic lymph node metastases, as a short axis equal to or larger than 1 cm of the lymph nodes is the only criterion used to diagnose lymph node involvement. However, as also benign lymph nodes, such as inflammatory lymph nodes, may exceed this threshold, this criterion has only a low diagnostic value. In a metaanalysis, it could be shown that the pooled sensitivity of the size criterion is 55%, with a sensitivity of 81%. By using this criterion only, 42% of lymph nodes larger than 1 cm would be overstaged, as they are benign, and 17% of metastases in lymph nodes smaller than 1 cm would be missed.

By using fludeoxyglucose positron emission tomography (FDG PET)/CT, the sensitivity could be increased to 80%, with a specificity of 88%. Consequently, PET/CT is recommended for patients planning to undergo curative therapy (surgery or radiotherapy) to exclude lymph node involvement. However, as FDG PET/CT also struggles with false-positive results, histological confirmation of enlarged and/or FDG-positive lymph nodes is required to confirm metastatic involvement. A negative FDG PET in normal-sized hilar or mediastinal lymph nodes in patients with a small tumours (<3 cm) virtually excludes lymph node metastases, and thus, further invasive staging is not necessary. However, in larger (≥3 cm) central tumours, even a negative FDG PET/CT does not exclude lymph node metastases and invasive staging should be performed.

Equally important to the diagnosis of lymph node involvement is the correct assignment of the lymph node location. Based on
the anatomic location, the involved lymph nodes are assigned to lymph node stations that are defined in the TNM atlas. Common pitfalls in the assignment of the appropriate lymph node station are the assignment of right vs left paratracheal lymph nodes. Importantly, the border between the right and left paratracheal lymph nodes is not the midline of the trachea, but the left lateral wall of the trachea. A common misclassification of lymph nodes can also occur at the border between the lower paratracheal lymph nodes and hilar lymph nodes. On the right side, the lower aspect of the azygos vein separates the lower paratracheal lymph nodes from the hilar lymph nodes (Figure 6); on the left side, this border is defined by the upper aspect of the main pulmonary artery. In case of doubt, coronal reformations are helpful to identify the anatomic landmarks to determine the appropriate lymph node station. Some lymph node stations in the thorax (i.e. anterior, middle, and posterior diaphragmatic nodes, intercostal nodes, internal mammary nodes, retrocrural nodes, and axillary nodes) are not included in the International Association for the Study of Lung Cancer lymph node map at all. Therefore, it is unclear whether they are classified as N3 or M1 disease (Figure 7). Axillary lymph node metastases are seen in <1% of patients with NSCLC at the time of presentation and are associated with other M1 features in ~50% of cases. In the authors’ personal experience, however, lymph node metastasis in the above-mentioned lymph node stations rarely occurs without other evidence of advanced tumour stage (i.e. tumour size, lymph node metastasis, distant metastasis) that drive the tumour staging.

Metastatic disease

Approximately 20–50% of patients with lung cancer have distant metastases at the time of initial staging, with bone, brain, adrenal, and liver being the most common locations for metastasis. Importantly, some studies have shown that metastasis can occur at the time of angiogenesis when lesions are as small as 1–2 mm. In the TNM staging system, distant metastases are described using the M descriptor.

The M1a category describes intrathoracic metastases, such as one or more additional nodules in the contralateral lung or a tumour with malignant pleural or pericardial nodules or effusion.

Malignant pleural or pericardial effusion

Malignant pleural or pericardial effusion and or pleural or pericardial metastases are defined as M1a. Up to 16% of patients with NSCLC have malignant pleural effusion at presentation. The sensitivity and specificity of CT for reporting malignant pleural effusion are 62–75%, and 72–78%, respectively. Imaging features that suggest malignancy are nodular pleural thickening, mediastinal pleural thickening, and parietal pleural thickening >1 cm. However, with a negative predictive value of ~65%, approximately one in every three patients with suspected malignant pleural disease and pleural effusion, without any other radiological signs of malignancy, will have underlying malignant disease. Thus, in case of equivocal findings on CT, patients should undergo pleural tap or invasive pleural biopsies.

Extrathoracic metastases

Extrathoracic metastases are subdivided into two subcategories, namely, M1b and M1c. The M1b category describes one solitary extrathoracic metastases in one single organ. M1c is defined by the presence of two or more extrathoracic metastases. The subclassification of extrathoracic metastases into M1b and M1c was introduced in the eighth edition of the TNM staging system, acknowledging the difference in survival rates between M1b and M1c.
The reclassified descriptors not only provide an enhanced definition of metastatic disease and have a better ability to predict prognosis, but also maintain the compatibility with the previous existing descriptors of the seventh edition.

PET-CT proved very informative about metastatic spread in NSCLC, with an ability to detect unsuspected metastasis in up to 28% of patients, and also had an impact on management in up to 53% of patients.\(^27\)

**Bone metastases**

Approximately 35% of patients with lung cancer will develop bone metastasis during the course of their disease.\(^28\)
CT delivers a high spatial resolution of cortical and trabecular bone to detect bone metastases. The availability of dedicated bone algorithms in acquisition protocols, the ability to adjust the window width and level, and the possibility of MPRs results in a higher sensitivity for CT compared to plain radiography in detecting both osteolytic and osteosclerotic metastases. Bone metastasis in lung cancer can be osteolytic, osteoblastic, or mixed, but are predominantly lytic on CT imaging. All morphologic types of baseline metastatic lesions may become sclerotic lesions if there is a therapeutic response. In contrast, if a therapeutic response is not completely achieved, different patterns are recognised. A meta-analysis showed a higher sensitivity (92% vs 87%) and specificity (98% vs 94%) for the detection of bone metastases when CT was combined with 18F-FDG PET.29

The accuracy of bone scintigraphy in the detection of bone metastasis was 87 vs 98% for FDG-PET/CT. PET scanning is more sensitive and accurate than bone scanning for the detection of skeletal metastases (Figure 8), and is, therefore, recommended for all patients scheduled for curative surgery to exclude distant metastases.14,30

Bone islands can mimic sclerotic metastasis on CT imaging, but can usually be differentiated by their high attenuation values measured on CT. Another commonly encountered pitfall are haemangiomas of the vertebral body. The classical polka-dot appearance of haemangiomas may not be present ubiquitously. Some haemangiomas may exhibit a tracer uptake on PET-CT and this may further add to confounding clinical questions. In a majority of these instances when PET findings are positive and CT is negative, MR imaging may be the problem-solving tool. Both T1 and more advanced techniques as a modified Dixon TSE-T2 sequences show excellent sensitivity and specificity for the detection of bone metastasis.31 False-negative results on FDG PET/CT may be seen in the case of osteoblastic formations, as bone matrix proliferation reduces the glycolytic activity essential for FDG uptake.

**Adrenal gland metastases**

Metastasis to the adrenal glands is common in patients with NSCLC and is usually accompanied by metastases in other organs, although it can present as oligometastatic disease. It is essential to distinguish commonly occurring benign entities of the adrenal gland, such as adenomas, from a metastatic lesion. The prevalence of adrenal adenoma is reported to be related to age; the frequency of unsuspected adenoma is 0.5% in patients aged 20–29 years and 7% in those older than 70 years.32

In lipid-rich adenomas, the non-invasive diagnosis relies on the proof of fat components. On CT, attenuation values below 10 Hounsfield unit (HU) in regions of interest (ROIs) encompassing two-thirds of the circumference of the region are highly specific for adenomas.33

As one-third of adrenal adenomas have a low lipid content, CT attenuation values above 10 HU do not exclude adenomas. To diagnose lipid-poor adenomas, contrast-enhanced CT scans or PET/CT scans showing metabolically active, bilateral adrenal gland metastasis (arrow). FDG, fludeoxyglucose; PET, positron emission tomography.
MRI are performed. MRI using chemical shift imaging has a higher sensitivity for the detection of lipids than CT, and is thus indicated in adrenal lesions with attenuation values between 10 and 20 HU. Combined chemical-shift and dynamic-MR imaging was shown to have a sensitivity of 91% and a specificity of 94% in the differentiation between benign and malignant adrenal lesions. For adenomas with CT attenuation values greater than 20 HU, washout CT is superior to chemical shift imaging.

PET/CT and MRI are useful in distinguishing benign and malignant adrenal masses. PET/CT was more sensitive than MRI in detecting adrenal metastases, with a sensitivity of 91% and a specificity of 90% when compared to histopathology. PET/CT was also more accurate in detecting metastases in patients with NSCLC, with a sensitivity of 89% and a specificity of 90%.

Brain metastases
Contrasted-enhanced MRI has a higher sensitivity for the detection of brain metastasis compared to CT and PET. In the March 2019 revisions of the NICE guideline, contrast-enhanced CT in patients with Stage II NSCLC having treatment with curative intent is recommended. In contrast, in patients with Stage III NSCLC having treatment with curative intent contrast-enhanced MRI is recommended. In addition, in patients with neurological symptoms, MRI of the brain should be performed.

Liver metastases
Isolated liver metastases have been reported in approximately 3–4% of NSCLC patients. Although the characteristic CT appearance in a triple-phase scan is a hypodense, hypoenhancing lesion, a subset of liver metastases may rarely manifest as hypoenhancing lesions, particularly when there is small cell neuroendocrine differentiation in the primary lung cancer. This may sometimes be confounded with a commonly occurring benign entity of the liver, such as a haemangioma. Although MRI has a higher accuracy in the detection of liver metastases compared to CT, it is not routinely recommended.

Soft tissue metastases
The lung, followed by the kidney and the colon, is the most common primary carcinoma site that leads to clinically recognised soft-tissue metastases. Relevant differentials of soft tissue metastases include injection site granulomas, atheromas, and neurogenic tumours. On PET-CT, false-positive results may be caused by foci of brown fat, but the typical location at the neck, paravertebral, mediastinal, and axillary regions may provide a clue to the diagnosis.

CONCLUSION
The TNM in its eighth edition provides a detailed framework by which to describe the anatomical extent of disease in patients with lung cancer. Despite several advantages compared to the former version, some limitations remain. It is important for radiologists to recognise these limitations. In those cases,
radiologists should be aware of the following general rule stated in the manuscript. "If there is doubt concerning the correct T, N, or M category to which a particular case should be allotted, the lower (i.e. less advanced) category should be chosen." Applying this rule in case of uncertainty could give patient the choice of doubt and enable the attempt of a curative treatment.

REFERENCES

1. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11: 39–51. doi: https://doi.org/10.1016/j.jtho.2015.09.009

2. Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, et al. The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol 2015; 10: 990–1003. doi: https://doi.org/10.1097/TO.0000000000000559

3. Travis WD, Asamura H, Bankier AA, Beasley MB, Detterbeck F, Dieder Berlin, et al. The IASLC lung cancer staging project: proposals for coding T categories for solid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2016; 11: 1204–23. doi: https://doi.org/10.1016/j.jtho.2016.03.025

4. Bankier AA, MacMahon H, Goo JM, Rubin GD, Schaefer-Prokop CM, Naidich DP. Recommendations for measuring pulmonary nodules at CT: a statement from the Fleischner Society. Radiology 2017; 285: 584–600. doi: https://doi.org/10.1148/radiol.2017162894

5. Gerbaudo VH, Julius B. Anatomo-metabolic characteristics of atelectasis in F-18 FDG-PET/CT imaging. Eur J Radiol 2007; 64: 401–5. doi: https://doi.org/10.1016/j.ejrad.2007.08.013

6. Beer L, Oberndorfer F, Silva M, Prosch H. Radiological Signs of Tumor Dissemination. The Thorax: Springer; 2020. pp. 35–46.

7. Kajiwara N, Akata S, Uchida O, Usuda J, Ohira T, Kawate N, et al. Cine MRI enables better therapeutic planning than CT in cases of possible lung cancer chest wall invasion. Lung Cancer 2010; 69: 203–8. doi: https://doi.org/10.1016/j.lungcan.2009.10.016

8. Yamashiro T, Moriya H, Tsukakimoto M, Nagatani Y,Kimoto T, Murayama S, et al. Preoperative assessment of parietal pleural invasion/adhesion of subpleural lung cancer: advantage of software-assisted analysis of 4-dimensional dynamic ventilation computed tomography. Eur Radiol 2019; 29: 5247–52. doi: https://doi.org/10.1007/s00330-019-06131-w

9. Seo JS, Kim YJ, Choi BW, Choe KO. Usefulness of magnetic resonance imaging for evaluation of cardiovascular invasion: evaluation of sliding motion between thoracic mass and adjacent structures on cine MR images. J Magn Reson Imaging 2005; 22: 234–41. doi: https://doi.org/10.1002/mrri.20378

10. Detterbeck FC, Nicholson AG, Franklin WA, Marom EM, Travis WD, Girard N, et al. The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming eighth edition of the TNM classification. J Thorac Oncol 2016; 11: 639–50. doi: https://doi.org/10.1016/j.jtho.2016.01.024

11. Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ED: American College of chest physicians evidence-based clinical practice guidelines. Chest 2013; 143(S Suppl): e211S–50. doi: https://doi.org/10.1378/chest.12-2355

12. Alongi F, Ragusa P, Montemaggi P, bona CM. Combining independent studies of diagnostic fluorodeoxyglucose positron-emission tomography and computed tomography in mediastinal lymph node staging for non-small cell lung cancer. Tumori 2006; 92: 327–33. doi: https://doi.org/10.1177/030089160609200412

13. Schmidt-Hansen M, Baldwin DR, Hasler E, Zamora J, Abraira V, Roqué I Figuls E, Zamora J, Abraira V, Roqué I. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Database Syst Rev 2014; CD009519. doi: https://doi.org/10.1002/14651858.CD009519.pub2

14. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2017; 28: iv1–21. doi: https://doi.org/10.1093/annonc/mdw222

15. Novello S, Barlesi F, Caligano R, Cufer T, Ekman S, Levrà MG, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27(suppl 5): v1–27. doi: https://doi.org/10.1093/annonc/mdw326

16. Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med 2017; 377: 849–61. doi: https://doi.org/10.1056/NEJMr1703413

17. Beer L, Hochmair M, Prosch H. Pitfalls in the radiological response assessment of immunotherapy. Memo 2018; 11: 138–43. doi: https://doi.org/10.1007/s12254-018-0389-x

18. Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P, et al. The IASLC lung cancer staging project: proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2009; 4: 568–77. doi: https://doi.org/10.1097/JTO.0b013e3181f8d8e2

19. El-Shereif AH, Lau CT, Obuchowski NA, Mehta AC, Rice TW, Blackstone EH. Cross-disciplinary analysis of lymph node classification in lung cancer on CT scanning. Chest 2017; 151: 776–85. doi: https://doi.org/10.1016/j.chest.2016.09.016

20. Satoh H, Ishikawa H, Kagohashi K, Kurushima K, Sekizawa K. Axillary lymph node metastasis in lung cancer. Med Oncol 2009; 26: 147–50. doi: https://doi.org/10.1007/s12032-008-9907-4

21. Eberhardt WEE, Mitchell A, Crowley J, Kondo H, Kim YT, Turrisi A, et al. The IASLC lung cancer staging project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of
l lung cancer. J Thorac Oncol 2015; 10: 1515–22. doi: https://doi.org/10.1097/JTO.0000000000000673
22. Folkman J. Clinical applications of research on angiogenesis. New England Journal of Medicine 1995; 333: 1757–63. doi: https://doi.org/10.1056/NEJM199512283833260
23. Quint LE, Tummala S, Brisson LJ, Francis IR, Krupnick AS, Kazerooni EA, et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg 1996; 62: 246–50. doi: https://doi.org/10.1016/0003-4975(96)00220-2
24. Morgensztern D, Waqar S, Subramanian J, Trinkaus K, Govindan R. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thorac Oncol 2012; 7: 1485–9. doi: https://doi.org/10.1097/JTO.0b013e318267223a
25. Hallifax RJ, Haris M, Corcoran JP, Leyakathalikhan S, Brown E, Srikantharaja et al. Role of CT in assessing pleural malignancy prior to thoracoscopy. Thorax 2012; 67: 195–222. doi: https://doi.org/10.1136/thoraxjnl-2012-206054
26. Tufman A, Kahnert K, Kauffmann-Guerrero D, Manopov F, Milger K, Müller-Lisse U, et al. Clinical relevance of the M1b and M1c descriptors from the proposed TNM 8 classification of lung cancer. Strahlenther Onkol 2017; 193: 392–401. doi: https://doi.org/10.1007/s00066-017-1118-9
27. Gallamini A, Zwarthoed C, Borra A. Positron emission tomography (PET) in oncology. Cancers 2014; 6: 1821–89. doi: https://doi.org/10.3390/cancers6041821
28. D’Antonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, et al. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol 2014; 6: 101–14. doi: https://doi.org/10.1177/1758834014521110
29. Xu X, Huang X, Yan W, Wu L, Dai K. A meta-analysis of 18FDG-PET-CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol 2012; 81: 1007–15. doi: https://doi.org/10.1016/j.ejrad.2011.01.126
30. Carr LL, Finigan JH, Kern JA. Evaluation and treatment of patients with non-small cell lung cancer. Med Clin North Am 2011; 95: 1041–54. doi: https://doi.org/10.1016/j.mcna.2011.08.001
31. Hahn S, Lee YH, Suh J-S. Detection of vertebral metastases: a comparison between the modified Dixon turbo spin echo T1 weighted MRI and conventional T1 weighted MRI: a preliminary study in a tertiary centre. Br J Radiol 2018; 91: 20170782. doi: https://doi.org/10.1016/j.bjr.20170782
32. Heinz-Peer G, Höningsschnabl S, Schneider B, Niederle B, Kaserer K, Lechner G. Characterization of adrenal masses using MR imaging with histopathologic correlation. AJR Am J Roentgenol 1999; 173: 15–22. doi: https://doi.org/10.2214/ajr.173.1.10397092
33. Schieda N, Siegelman ES. Update on CT and MRI of adrenal nodules. AJR Am J Roentgenol 2017; 208: 1206–17. doi: https://doi.org/10.2214/ajr.16.17758
34. Jana S, Zhang T, Milstein DM, Isaai CR, Blaufuss MD. Fdg-Pet and CT characterization of adrenal lesions in cancer patients. Eur J Nucl Med Mol Imaging 2006; 33: 29–35. doi: https://doi.org/10.1007/s00259-005-1915-8
35. Wu Q, Luo W, Zhao Y, Xu F, Zhou Q. The utility of 18F-FDG PET/CT for the diagnosis of adrenal metastasis in lung cancer: a PRISMA-compliant meta-analysis. Nucl Med Commun 2017; 38: 1117–24. doi: https://doi.org/10.1097/MNM.0000000000000757
36. Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A. 18F-Fdg PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 2001; 42: 1795–9.
37. Maconachie R, Mercer T, Navani N, McVeigh G. Lung cancer: diagnosis and management: summary of updated NICE guidance. 364. BMJ: British Medical Journal (Online); 2019.
38. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faire-Finn C, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2018; 29: iv192–237. doi: https://doi.org/10.1093/annonc/mdy275
39. Kagohashi K, Satoh H, Ishikawa H, Ohitsuka M, Sekizawa K. Liver metastasis at the time of initial diagnosis of lung cancer. Med Oncol 2003; 20: 25–8. doi: https://doi.org/10.1385/MO:20:1:25
40. Scharitzen M, Ba-Ssalamah A, Ringl H, Kölblinger C, Grünerberger T, Weber M, et al. Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation. Eur Radiol 2013; 23: 2187–96. doi: https://doi.org/10.1007/s00330-013-2824-z
41. Perisano C, Spinelli MS, Graci C, Scaramuzzo L, Marzetti E, Barone C, et al. Soft tissue metastases in lung cancer: a review of the literature. Eur Rev Med Pharmacol Sci 2012; 16: 1908–14.
42. Vlahos I. Dilemmas in lung cancer staging. Radial Clin North Am 2018; 56: 419–35. doi: https://doi.org/10.1016/j.rcl.2018.01.010
43. Goldstraw P. International association for thoracic oncology: Orange Park. Editorial Rx Press 2009.